Back to Search Start Over

Physicians' choices in the first- and second-line management of type 2 diabetes in the Kingdom of Saudi Arabia

Authors :
Khalid Al-Rubeaan
Faisal A. Bana
Fayez G. Alruwaily
Eman Sheshah
Dhekra Alnaqeb
Awad M. AlQahtani
Diaa Ewais
Nassr Al Juhani
Abdul-hameed Hassan
Amira M. Youssef
Source :
Saudi Pharmaceutical Journal, Vol 28, Iss 3, Pp 329-337 (2020)
Publication Year :
2020
Publisher :
Elsevier, 2020.

Abstract

Objectives: The DISCOVER study is a global, prospective, three- year- observational (non-interventional) study that was conducted in 37 countries throughout the world including Saudi Arabia and aimed to assess variations in treatment patterns and therapeutic outcomes in type 2 diabetic patients. The current manuscript is reporting data of DISCOVER study across different health sectors of various provinces in the Kingdom of Saudi Arabia. Methods: In this study, 519 Saudi type 2 diabetics, non-insulin users, aged 18 years or older, initiating second line therapy, were selected from nine health institutes, in four out of five provinces in Saudi Arabia. Data was collected at baseline (initiation of 2nd line therapy) by the treating physician using an electronic case report form (eCRF) via a web-based data capture system. Each selected subject was asked to complete four self-administered questionnaires. Results: The mean age of the studied population was 52.4 ± 11 years. Among the subjects selected from the nine medical centers, 55% were men, with almost 65% between the ages of 46 and 65 years. The oral agent used as 1st line in the majority of patients was metformin, prescribed in 89.2% of the study cohort. In the second line, sitagliptin was the most frequently used, at 61.8%. followed by gliclazide, glibenclamide, and glimepiride at 35.6%, 13.1%, and 12.7%, respectively. Conclusion: Metformin, with or without sulfonylureas, is the most commonly prescribed first-line treatment for patients with type 2 diabetes, managed either in governmental institutions, or in the private sector. The most common second line drugs were DPP4 inhibitors, mainly sitagliptin, followed by the third and second generation of sulfonylureas. Drug affordability was not an issue, since the vast majority of the patients received medication free of charge. Keywords: Discover Type 2 diabetes, First line management, Second line management

Subjects

Subjects :
Therapeutics. Pharmacology
RM1-950

Details

Language :
English
ISSN :
13190164
Volume :
28
Issue :
3
Database :
Directory of Open Access Journals
Journal :
Saudi Pharmaceutical Journal
Publication Type :
Academic Journal
Accession number :
edsdoj.bbc78fcf809e4d53b244bbe6f915f5ef
Document Type :
article
Full Text :
https://doi.org/10.1016/j.jsps.2020.01.014